NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CMMB

Chemomab Therapeutics Ltd ADR

Apr 23 • 04:00PM ET

1.20

Dollar change +0.03
Percentage change 2.56	%

Healthcare • Biotechnology • Israel • NASD

Peers: VRTX ONC MDGL NBIX AKRO MNOV ARDX TXMD ETNB PBYI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	12.13%	Shs Outstand	18.86M	Perf Week	-0.83%
Market Cap	22.63M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	16.57M	Perf Month	-3.23%
Income	-14.01M	PEG	-	EPS next Q	-0.01	Inst Own	12.88%	Short Float	1.54%	Perf Quarter	-42.58%
Sales	0.00M	P/S	-	EPS this Y	-806.98%	Inst Trans	-12.38%	Short Ratio	0.71	Perf Half Y	-23.57%
Book/sh	0.72	P/B	1.67	EPS next Y	2.56%	ROA	-71.63%	Short Interest	0.26M	Perf Year	76.47%
Cash/sh	0.76	P/C	1.58	EPS next 5Y	-	ROE	-91.76%	52W Range	0.60 - 2.55	Perf YTD	-33.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.20%	ROI	-101.91%	52W High	-52.94%	Beta	0.52
Dividend TTM	-	Quick Ratio	4.98	Sales past 5Y	0.00%	Gross Margin	-	52W Low	99.00%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	4.98	EPS Y/Y TTM	57.93%	Oper. Margin	-	RSI (14)	50.28	Volatility	8.16% 12.67%
Employees	16	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	40.28%	Payout	-	Rel Volume	0.31	Prev Close	1.17
Sales Surprise	-	EPS Surprise	85.89%	Sales Q/Q	-	Earnings	Mar 03 BMO	Avg Volume	361.31K	Price	1.20
SMA20	9.40%	SMA50	-12.29%	SMA200	-22.46%	Trades		Volume	113,626	Change	2.56%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-24	Initiated	Maxim Group	Buy	$4
May-06-24	Upgrade	Oppenheimer	Perform → Outperform	$6
Dec-19-23	Resumed	ROTH MKM	Buy	$7

Apr-21-25 08:00AM	Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Apr-15-25 08:00AM	Chemomab Announces New Medical and Clinical Appointments (GlobeNewswire)
Mar-27-25 08:30AM	Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers (GlobeNewswire) -5.17%
Mar-06-25 08:00AM	New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis (GlobeNewswire) +5.71%
Mar-03-25 08:00AM	Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.12%
07:00AM	Loading…
Feb-19-25 07:00AM	Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis (GlobeNewswire)
Feb-03-25 07:00AM	Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-03-24 07:00AM	Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit (GlobeNewswire)
Nov-19-24 07:00AM	Oral Presentation at AASLD The Liver Meeting 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis (GlobeNewswire)
Nov-14-24 07:00AM	Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-30-24 07:00AM	Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
Oct-15-24 07:00AM	Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting 2024 (GlobeNewswire) +9.17%
Oct-01-24 07:00AM	Chemomab Therapeutics to Present at October 2024 Investor Conferences (GlobeNewswire)
Aug-28-24 07:00AM	Chemomab Therapeutics to Present at September 2024 Investor Conferences (GlobeNewswire) +12.73%
Aug-21-24 07:00AM	Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Loading…
Aug-12-24 07:00AM	Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
Jul-30-24 09:00AM	Chemomab Therapeutics Announces Closing of $10 Million Private Placement (GlobeNewswire)
Jul-26-24 07:00AM	Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +6.72%
Jul-25-24 07:38AM	Chemomab Therapeutics Announces $10 Million Private Placement (GlobeNewswire) -16.20%
07:00AM	Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis (GlobeNewswire)
Jun-27-24 12:00PM	Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-18-24 07:00AM	Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis (GlobeNewswire) +11.54%
Jun-06-24 07:00AM	Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference (GlobeNewswire) -11.64%
May-17-24 07:00AM	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences (GlobeNewswire)
May-10-24 09:55AM	Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-09-24 11:57AM	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024 (InvestorPlace) +11.72%
07:00AM	Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:00AM	Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire) -18.42%
May-02-24 07:00AM	Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference (GlobeNewswire)
Apr-24-24 07:00AM	Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
07:00AM	Loading…
Apr-18-24 07:00AM	Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis (GlobeNewswire) +18.64%
Apr-02-24 07:00AM	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 (GlobeNewswire)
Mar-25-24 07:06AM	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis (GlobeNewswire) -5.60%
Mar-07-24 12:53PM	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.63%
07:00AM	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-05-24 07:00AM	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference (PR Newswire)
Feb-20-24 07:00AM	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases (PR Newswire) +6.37%
Feb-14-24 07:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update (PR Newswire)
Feb-05-24 07:00AM	Chemomab Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Jan-30-24 07:00AM	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis (PR Newswire) +7.41%
Jan-03-24 07:00AM	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 (PR Newswire)
Nov-16-23 07:00AM	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis (PR Newswire) -19.22%
Nov-15-23 07:00AM	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis (PR Newswire) +33.93%
Nov-13-23 08:00AM	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting 2023 (PR Newswire) -6.78%
Nov-09-23 08:00AM	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire) -6.10%
Nov-06-23 04:15PM	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement (PR Newswire) -6.78% -6.21%
Oct-30-23 07:00AM	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update (PR Newswire) -7.15%
Oct-26-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Sep-28-23 07:00AM	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference (PR Newswire)
Aug-29-23 07:00AM	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 08:00AM	Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Jun-28-23 07:00AM	Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis (PR Newswire) -5.37%
Jun-26-23 07:00AM	Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 (PR Newswire) +28.00%
Jun-21-23 07:00AM	Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 (PR Newswire) -13.22%
Jun-05-23 07:00AM	Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update (PR Newswire)
Jun-02-23 09:00AM	Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis (PR Newswire) +8.12%
May-24-23 07:00AM	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences (PR Newswire)
May-11-23 06:00AM	Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Apr-26-23 07:00AM	Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference (PR Newswire)
Apr-19-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-12-23 07:00AM	Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Mar-29-23 08:30AM	Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023 (PR Newswire)
Mar-17-23 07:00AM	Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-06-23 07:00AM	Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Feb-21-23 07:00AM	Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis (PR Newswire) +16.84%
Jan-03-23 07:00AM	Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients (PR Newswire) -8.13%
Dec-21-22 07:00AM	Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PR Newswire)
Nov-30-22 07:00AM	Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy (PR Newswire)
Nov-11-22 06:00AM	Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-09-22 08:00AM	Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 (PR Newswire)
Nov-01-22 07:00AM	Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Oct-28-22 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Aug-12-22 06:00AM	Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
06:00AM	Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities (PR Newswire)
Aug-01-22 07:00AM	Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Jun-27-22 08:00AM	Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis (PR Newswire)
Jun-21-22 07:00AM	Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors (PR Newswire) +5.42%
Jun-09-22 09:00AM	Chemomab Therapeutics to Present at June Investor and Scientific Conferences (PR Newswire)
Jun-02-22 07:00AM	Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 (PR Newswire)
May-18-22 07:00AM	Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 06:00AM	Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-04-22 07:00AM	Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-23-22 07:00AM	Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit (PR Newswire)
Mar-14-22 08:00AM	Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis (PR Newswire) -5.48%
Mar-09-22 06:00AM	Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-02-22 08:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update (PR Newswire)
Feb-10-22 08:00AM	Chemomab Therapeutics to Present at Aegis Virtual Conference (PR Newswire)
Jan-04-22 07:00AM	Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations (PR Newswire)
Dec-20-21 08:00AM	Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference (PR Newswire)
Dec-16-21 04:05PM	Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board (PR Newswire)
Dec-03-21 08:00AM	Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer (PR Newswire) -11.27%
Dec-02-21 07:00AM	Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis (PR Newswire)
Nov-23-21 05:34AM	Insiders who purchased Chemomab Therapeutics Ltd. (NASDAQ:CMMB) earlier this year lose an additional US$78k as the stock sinks to US$8.99 (Simply Wall St.) -5.67%
Nov-12-21 07:00AM	Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Nov-10-21 07:00AM	Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021 (PR Newswire) -5.01%
Nov-09-21 07:00AM	Chemomab to Present at Stifel 2021 Virtual Healthcare Conference (PR Newswire)
Nov-08-21 07:00AM	Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer (PR Newswire)
Oct-26-21 08:53AM	Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis (PR Newswire)
Oct-15-21 11:42AM	Wonderland: Miami to Showcase the Business of Psychedelic Medicine (Exec Edge)
Sep-27-21 07:00AM	Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis (PR Newswire)

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OrbiMed Israel Partners Limite	Owner	Sep 12 '24	Proposed Sale	2.03	500,000	1,015,000		Sep 12 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMMB

Chemomab Therapeutics Ltd ADR

Upgrade your FINVIZ experience